Supportive Hematological Disorders Studies

Non-therapeutic protocols address such issues as side effects or long-term effects of therapy, quality of life, making testing easier on the children, prevention of pain, and issues related to nutrition and stress. There are also tissue and blood banking protocols for laboratory researchers who are studying diseases and searching for underlying causes and cures. The research at St. Jude is designed to include all aspects related to the care of sick children and their families.

St. Jude Clinical Trials

INSIGHT-HD: Investigating the Genetics of Hematologic Diseases

Diseases Treated:

Non-malignant blood diseases (non-therapeutic)


  • Receiving therapy or a consultation for a non-malignant blood disorder
  • Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing
View Trial

LEAPS: Understanding Sickle Cell Disease Transition to Adult Care

Diseases Treated:

Sickle Cell Disease


This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.

  • Diagnosis of sickle cell disease (SCD)
  • 16 to 20 years old
  • English is primary language
View Trial

REHASH: Barriers to Hydroxyurea Adherence for Sickle Cell Disease

Diseases Treated:

Sickle cell disease


This study is limited to patients living in the Memphis, Tennessee region.

Phase I

Phase II

  • Diagnosis of sickle cell disease
  • Between 15 and 44.9 years old
  • Receiving hydroxyurea treatment for sickle cell disease
  • Owns a smart phone
  • Not currently receiving text messages for improving hydroxyurea adherence
  • Not currently undergoing hydroxyurea dose escalation
  • Not on any investigational new drug intervention study for sickle cell disease
View Trial

Collaborative Clinical Trials

PKiDS: Pyruvate Kinase Deficiency (PKD) Natural History Study

Diseases Treated:

Pyruvate kinase deficiency (PKD)


This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • Participants of all ages with biochemically or genetically diagnosed PKD.
  • Participants with a hemolytic anemia and a family member with genetically diagnosed PKD.
  • The participant or the guardian of the participant is willing and able to give written informed consent and/or assent.
View Trial